Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JMKX003142 QTc Study in Healthy Participants
NCT07470177Phase 1Not yet recruiting
- Sponsor
- Jemincare
- Start
- Mar 2026
- Primary completion
- May 2026
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial of JMKX003142 in autosomal dominant polycystic kidney disease (ADPKD), sponsored by Jemincare. Primary endpoint: Placebo-corrected change from baseline QT interval at 24 hours. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
JMKX003142
03
Conditions
autosomal dominant polycystic kidney disease (ADPKD)
Beyond the preview
Go deeper on NCT07470177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07470177.